RxDoctor Payments Data

Courtney Drain

Family · Searcy, ARNPI 1285397240

Payments from drug & device makers

$1,472in general payments, 2019–2025

Across 75 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$810
  • AstraZeneca$163
  • Xeris Pharmaceuticals, Inc.$160
  • GSK$46
  • Braeburn Inc.$45
  • Alkermes, Inc.$42
  • plus $205 from 9 others

What the payments were for

  • Food & beverage$1,472100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,472 in reported general payments places this provider in the 75th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$990
Medicare patients
33
Services billed
48

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide59$79,775
JardianceEmpagliflozin57$63,905
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$55,621
OzempicSemaglutide42$46,338
EliquisApixaban44$32,391
VemlidyTenofovir Alafenamide12$20,049
JanuviaSitagliptin Phosphate11$11,058
Breo ElliptaFluticasone/Vilanterol28$10,666
Bevespi AerosphereGlycopyrrolate/Formoterol Fum17$10,087
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$9,932
LinzessLinaclotide14$9,472
SymbicortBudesonide/Formoterol Fumarate20$4,549
Albuterol Sulfate HfaAlbuterol Sulfate139$3,151
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl19$2,260
Gabapentin87$1,391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$41$79,77559 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$46$76,219120 claims
Novo NordiskOzempic$17$46,33842 claims
AstraZenecaBevespi Aerosphere, Symbicort$163$14,63637 claims
MerckJanuvia$15$11,05811 claims
AbbVieLinzess$810$9,47214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,103 family providers in Arkansas.

Other family in Searcy

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →